Drug & Medication
Table of Contents
The 2011–20 projection period will see the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise, while new launches include the first once-weekly GLP-1 agonists and the oral SGLT-2 inhibitor class, to compete in an increasingly crowded treatment algorithm in type 2 diabetes. This market research report was updated in May 2012 to reflect recent developments in the industry ....More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Amrita
+1 718 303 2019
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute o ...
PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon, such as ...
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of ...
... Hg introduces new recommendations designed to promote safer use of angiotensin converting enzyme inhibitors (aceis) and angiotensin receptor blockers (arbs) first-line and later-line treatment should now ...
... vaccination 1988: before the global polio eradication initiative endemic non-endemic who. Global polio eradication initiative. Available at: http ...
Reportlinker.com © Copyright 2014. All rights reserved.